Cerus (STU:CU2) Accounts Payable & Accrued Expense : €22.0 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Cerus Accounts Payable & Accrued Expense?

Cerus's quarterly accounts payable & accrued expense declined from Sep. 2023 (€44.4 Mil) to Dec. 2023 (€28.7 Mil) and declined from Dec. 2023 (€28.7 Mil) to Mar. 2024 (€22.0 Mil).

Cerus's annual accounts payable & accrued expense increased from Dec. 2021 (€37.9 Mil) to Dec. 2022 (€38.4 Mil) but then declined from Dec. 2022 (€38.4 Mil) to Dec. 2023 (€28.7 Mil).

Cerus Accounts Payable & Accrued Expense Historical Data

The historical data trend for Cerus's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Accounts Payable & Accrued Expense Chart

Cerus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

27.39

27.10

37.86

38.35

28.65

Cerus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															41.00	41.56	44.43	28.65	21.98

Cerus Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Cerus (STU:CU2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (STU:CU2) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

CERS:USA

Address

1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520

Website

http://www.cerus.com

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Cerus (STU:CU2) Headlines

No Headlines